Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Wednesday

Key Points

• Abeona Therapeutics will report Q1 2026 results before the market opens on Wednesday, May 13, 2026, with analysts forecasting EPS of ($0.34) and revenue of $4.572 million and a conference call at 8:30 AM ET.
• In its most recent quarter Abeona reported EPS of ($0.34) (beating the $0.35 loss estimate by $0.01) but missed revenue expectations ($3.0M vs. $5.65M), and analysts model roughly ‑$1 EPS for the current fiscal year and $1 EPS next year.
• The stock trades around $6.04 with a market cap of about $343M, ~80.6% institutional ownership, and a MarketBeat consensus of “Moderate Buy” with an average price target of $19.00 (four Buys, one Sell).

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Abeona Therapeutics to post earnings of ($0.34) per share and revenue of $4.5720 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.01. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.65 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

NASDAQ:ABEO traded up $0.21 during trading hours on Wednesday, reaching $6.04. 534,101 shares of the company's stock were exchanged, compared to its average volume of 1,181,594. The company has a market capitalization of $343.27 million, a P/E ratio of 5.86 and a beta of 1.35. Abeona Therapeutics has a 12 month low of $4.00 and a 12 month high of $7.54. The company has a quick ratio of 6.74, a current ratio of 6.93 and a debt-to-equity ratio of 0.05. The business's 50-day simple moving average is $4.99 and its two-hundred day simple moving average is $5.03.

Institutional Trading of Abeona Therapeutics

Several large investors have recently modified their holdings of the company. XTX Topco Ltd boosted its holdings in shares of Abeona Therapeutics by 25.4% during the 4th quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 9,979 shares during the period. Tang Capital Management LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter worth about $5,270,000. Balyasny Asset Management L.P. bought a new position in shares of Abeona Therapeutics during the 4th quarter worth about $3,118,000. J. Goldman & Co LP bought a new position in shares of Abeona Therapeutics during the 4th quarter worth about $2,102,000. Finally, AQR Capital Management LLC lifted its holdings in Abeona Therapeutics by 240.7% during the 4th quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company's stock valued at $604,000 after purchasing an additional 80,908 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a report on Thursday, March 19th. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, March 17th. Weiss Ratings restated a "sell (d+)" rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Finally, Oppenheimer restated an "outperform" rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.